HDT Bio
HDT Bio develops advanced RNA vaccine products to treat and prevent infectious diseases and cancers, utilizing proprietary LION™ technology and the AMPLIFY vaccine platform.
Services
HDT Bio focuses on developing advanced RNA vaccine products targeted at treating and preventing infectious diseases and cancers. The company utilizes its proprietary LION™ technology, which is designed to enhance the delivery and efficacy of RNA vaccines. HDT Bio offers the AMPLIFY vaccine platform, combining self-amplifying RNA (repRNA) with LION™ technology. Through this, the company aims to create vaccines with improved immune responses and greater stability.
Products
HDT Bio's key products include RNA vaccine candidates and platforms designed for both preventative and therapeutic applications. A notable product is the first self-replicating RNA (repRNA) vaccine developed by HDT Bio, which has received regulatory authorization. Additionally, HDT-201, a thermo-stable and broad-spectrum intranasal RIG-I Agonist RNA SARS-CoV-2 antiviral candidate, is under development and has been recognized with a $1 million award from BLUE KNIGHT™ Resident QuickFire Challenge.
Technologies
HDT Bio employs cutting-edge technologies in its vaccine development. The LION™ technology is proprietary to HDT Bio and is instrumental in enhancing RNA vaccine delivery and performance. Their AMPLIFY platform is another notable technology that merges self-amplifying RNA (repRNA) with LION™ technology to boost vaccine effectiveness. The company is also working on saRNA vaccine technology, supported by up to $87.4M in prototype project funding from the U.S. government.
Partnerships
HDT Bio engages in various global partnerships to accelerate the delivery of advanced medicines. Collaborations include partnerships with prominent institutions and organizations such as Johnson & Johnson, the National Cancer Institute, the U.S. Department of Defense, and the University of Washington. These partnerships enable HDT Bio to leverage additional expertise and resources in advancing its vaccine and therapeutic development efforts.
Notable Achievements
HDT Bio has several notable achievements in the field of RNA vaccine development. The company developed the first self-replicating RNA (repRNA) vaccine to receive regulatory authorization. In recognition of its innovation, HDT Bio received a $1 million award from the BLUE KNIGHT™ Resident QuickFire Challenge. Additionally, HDT Bio was awarded up to $87.4M from the U.S. government for the development of saRNA vaccine technology. The company's participation in the World Vaccine Congress West Coast 2023 underscores its active role in the global vaccine development community.